<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01388816</url>
  </required_header>
  <id_info>
    <org_study_id>DRL-17822/CD/004</org_study_id>
    <nct_id>NCT01388816</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of DRL-17822 in Patients With Type II Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaNet</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a new drug, DRL-17822, is safe and effective in
      elevating high density lipoprotein cholesterol (HDL-C) and reducing low density lipoprotein
      cholesterol (LDL-C) in people with abnormal cholesterol levels that may put them at risk for
      heart disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease is a leading cause of death worldwide. Among cardiovascular disorders,
      coronary heart disease (CHD) caused by atherosclerosis is the most common cause of morbidity
      and mortality. Prevention, stabilization and regression of atherosclerotic plaques may have a
      major impact on reducing the risk of acute coronary events.

      LDL-C lowering agents, primarily the statins, are the current mainstay in the pharmacologic
      management of dyslipidemia. However even with stain use, residual CHD risk from dyslipidemia
      remains. Epidemiologic and observational studies have shown that HDL-C is also a strong
      independent predictor of CHD, suggesting that raising HDL-C levels might afford clinical
      benefit in the reduction of cardiovascular risk.

      Presently only niacin is approved by the FDA for HDL-C elevation and can raise HDL-C levels
      by 20-30%. However its use can be limited by a high incidence of flushing and, less commonly,
      by elevation of blood glucose and potential hepatic toxicity.

      Cholesteryl ester transfer protein (CETP) inhibitors are being explored for their ability to
      elevate HDL-C. A small molecule CETP inhibitor, torcetrapib, has been demonstrated to elevate
      HDL-C by 60-100%. However, a large clinical trial (ILLUMINATE) where it increased HDL-C by a
      mean of 72% compared to baseline was halted as it failed to show benefit. Post-hoc analysis
      of this study implicated an off-target increase in blood pressure as potentially
      counteracting any anti-atherosclerotic benefits. Post-hoc subgroup analysis showed that
      patients in the highest HDL-C quartile had a 57% reduction in the risk of cardiovascular
      events.

      Increased blood pressure appears to be specifically related to torcetrapib as two other small
      molecule CETP inhibitors, anacetrapib and dalcetrapib, have not shown this in clinical trials
      and have been well tolerated. DRL-17822 has also not shown elevation of blood pressure in
      either animals or in normal volunteers.

      This study will investigate the efficacy and tolerability of DRL-17822 as dyslipidemia
      monotherapy in patients with Type II hyperlipidemia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in HDL-C From Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>Percent change from baseline in HDL-C after 28 days of treatment in patients with Type II hyperlipidemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of DRL-17822</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of treatment-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Vital Signs Including Blood Pressure</measure>
    <time_frame>28 days</time_frame>
    <description>Vital sign abnormalities reported as treatment-emergent AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate Trough Levels of DRL-17822 in Plasma</measure>
    <time_frame>28 days</time_frame>
    <description>Trough levels of DRL-17822 in plasma after 28 days of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CETP Inhibition in Plasma</measure>
    <time_frame>28 days</time_frame>
    <description>Percent change from baseline in CETP Inhibition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Other Lipids and Apolipoproteins</measure>
    <time_frame>28 days</time_frame>
    <description>Change from baseline (LOCF, ITT population)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Type II Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DRL-17822 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DRL-17822 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DRL-17822 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRL-17822 or placebo</intervention_name>
    <description>DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast</description>
    <arm_group_label>Placebo capsule</arm_group_label>
    <arm_group_label>DRL-17822 50 mg</arm_group_label>
    <arm_group_label>DRL-17822 150 mg</arm_group_label>
    <arm_group_label>DRL-17822 300 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Type II hyperlipidemia having lipid values of HDL-C: males ≤ 44 mg/dL
             (≤1.13 mmol/L), females ≤ 54 mg/dL (≤1.39 mmol/L); LDL-C: ≥ 130 mg/dL (≥3.33 mmol/L);

          -  Male or female, 18 to 70 years of age, inclusive. Female patients must be
             postmenopausal or surgically sterile. Men, unless surgically sterile must practice
             birth control from screening until the end of the study;

          -  Ability and willingness to give written informed consent;

          -  No clinically significant abnormal findings on medical history, physical examination,
             vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory profiles of both
             blood and urine.

        Exclusion Criteria:

          -  Patients with significant cardiac disease such as myocardial infarction, heart
             failure, coronary or peripheral artery angioplasty, bypass graft surgery, severe or
             unstable angina pectoris, cardiac arrhythmias, hypertension or any other disease which
             requires treatment;

          -  Uncontrolled diabetes (HbA1c &gt; 8.0%);

          -  History of symptomatic cerebrovascular disease such as symptomatic carotid artery
             disease, cerebrovascular hemorrhage, transient ischemic attack or carotid
             endarterectomy or any disease which requires treatment;

          -  History of clinically significant hematologic, renal, hepatic, neurologic, endocrine,
             oncologic, pulmonary, immunologic or psychiatric disorders;

          -  Any current or recent (within 4 weeks of run-in) concomitant therapy (apart from
             paracetamol/acetaminophen and non-steroidal anti-inflammatory drugs [NSAIDs]).
             Patients on previous concomitant treatment may enter the study if the treatment has
             been discontinued, when appropriate and if ethically justified, at least four weeks
             prior to run-in;

          -  Body mass index (BMI)&gt; 35 kg/m(2);

          -  Positive for hepatitis B, C or HIV or known history or concurrent tuberculosis;

          -  Positive drug screen result (i.e., cocaine, opiates, amphetamine, cannabis,
             barbiturates, benzodiazepines and/or metadone);

          -  Pregnant, breast feeding or women of child-bearing potential;

          -  Regular use of non-drug therapies such as garlic supplements and St. John's Wort;

          -  Presence or history of alcoholism or drug abuse;

          -  Use of more than 21 units of alcohol per week for males or more than 14 units per week
             for females;

          -  Smoking within 3 months prior to screening;

          -  Relevant drug hypersensitivity or allergy or any serious adverse event reaction to
             lipid regulating agents;

          -  Administration of study drug in another drug study within 90 days prior to enrollment
             or participation in another drug trial from screening to last follow-up of this study;
             Any surgical or medical condition which makes the patient unsuitable to participate in
             the opinion of the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kent Allenby, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Reddy's Laboratories</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gniewkowo</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chernivtsi</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Poland</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2011</study_first_submitted>
  <study_first_submitted_qc>July 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2011</study_first_posted>
  <results_first_submitted>March 18, 2014</results_first_submitted>
  <results_first_submitted_qc>March 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 22, 2014</results_first_posted>
  <last_update_submitted>March 18, 2014</last_update_submitted>
  <last_update_submitted_qc>March 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized</keyword>
  <keyword>Double-Blind</keyword>
  <keyword>Placebo Controlled</keyword>
  <keyword>Parallel Arm</keyword>
  <keyword>Type II Hyperlipidemia</keyword>
  <keyword>Cholesteryl Ester Transferase Protein Inhibitor</keyword>
  <keyword>CETP Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Once daily after breakfast</description>
        </group>
        <group group_id="P2">
          <title>DRL-17822 50 mg</title>
          <description>Once daily after breakfast</description>
        </group>
        <group group_id="P3">
          <title>DRL-17822 150 mg</title>
          <description>Once daily after breakfast</description>
        </group>
        <group group_id="P4">
          <title>DRL-17822 300 mg</title>
          <description>Once daily after breakfast</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized patients</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Capsule</title>
          <description>Once daily after breakfast</description>
        </group>
        <group group_id="B2">
          <title>DRL-17822 50 mg</title>
          <description>Once daily after breakfast</description>
        </group>
        <group group_id="B3">
          <title>DRL-17822 150 mg</title>
          <description>Once daily after breakfast</description>
        </group>
        <group group_id="B4">
          <title>DRL-17822 300 mg</title>
          <description>Once daily after breakfast</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="44"/>
            <count group_id="B4" value="44"/>
            <count group_id="B5" value="176"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.0" spread="8.49"/>
                    <measurement group_id="B2" value="55.8" spread="9.93"/>
                    <measurement group_id="B3" value="54.2" spread="10.48"/>
                    <measurement group_id="B4" value="56.2" spread="10.74"/>
                    <measurement group_id="B5" value="55.8" spread="9.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in HDL-C From Baseline</title>
        <description>Percent change from baseline in HDL-C after 28 days of treatment in patients with Type II hyperlipidemia</description>
        <time_frame>28 days</time_frame>
        <population>Intention to treat (ITT) analysis with last observation carried forward (LOCF) for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O2">
            <title>DRL-17822 50 mg</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O3">
            <title>DRL-17822 150 mg</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O4">
            <title>DRL-17822 300 mg</title>
            <description>Once daily after breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in HDL-C From Baseline</title>
          <description>Percent change from baseline in HDL-C after 28 days of treatment in patients with Type II hyperlipidemia</description>
          <population>Intention to treat (ITT) analysis with last observation carried forward (LOCF) for missing data.</population>
          <units>percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="16.723" lower_limit="-10.8" upper_limit="17.3"/>
                    <measurement group_id="O2" value="84.2" spread="42.000" lower_limit="69.8" upper_limit="98.6"/>
                    <measurement group_id="O3" value="122.1" spread="60.035" lower_limit="107.8" upper_limit="136.3"/>
                    <measurement group_id="O4" value="160.6" spread="57.325" lower_limit="146.5" upper_limit="174.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of DRL-17822</title>
        <description>Incidence of treatment-related adverse events</description>
        <time_frame>28 days</time_frame>
        <population>Safety/ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O2">
            <title>DRL-17822 50 mg</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O3">
            <title>DRL-17822 150 mg</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O4">
            <title>DRL-17822 300 mg</title>
            <description>Once daily after breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of DRL-17822</title>
          <description>Incidence of treatment-related adverse events</description>
          <population>Safety/ITT Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment-related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Vital Signs Including Blood Pressure</title>
        <description>Vital sign abnormalities reported as treatment-emergent AEs</description>
        <time_frame>28 days</time_frame>
        <population>ITT/Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O2">
            <title>DRL-17822 50 mg</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O3">
            <title>DRL-17822 150 mg</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O4">
            <title>DRL-17822 300 mg</title>
            <description>Once daily after breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Vital Signs Including Blood Pressure</title>
          <description>Vital sign abnormalities reported as treatment-emergent AEs</description>
          <population>ITT/Safety Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate Trough Levels of DRL-17822 in Plasma</title>
        <description>Trough levels of DRL-17822 in plasma after 28 days of treatment</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DRL-17822 50 mg</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O2">
            <title>DRL-17822 150 mg</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O3">
            <title>DRL-17822 300 mg</title>
            <description>Once daily after breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate Trough Levels of DRL-17822 in Plasma</title>
          <description>Trough levels of DRL-17822 in plasma after 28 days of treatment</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315.6" spread="227.2"/>
                    <measurement group_id="O2" value="826.2" spread="1124.6"/>
                    <measurement group_id="O3" value="1341.3" spread="1121.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in CETP Inhibition in Plasma</title>
        <description>Percent change from baseline in CETP Inhibition</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O2">
            <title>DRL-17822 50 mg</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O3">
            <title>DRL-17822 150 mg</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O4">
            <title>DRL-17822 300 mg</title>
            <description>Once daily after breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CETP Inhibition in Plasma</title>
          <description>Percent change from baseline in CETP Inhibition</description>
          <population>ITT with LOCF</population>
          <units>percentage from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="0.3" upper_limit="14.1"/>
                    <measurement group_id="O2" value="60.5" lower_limit="53.4" upper_limit="67.6"/>
                    <measurement group_id="O3" value="79.7" lower_limit="72.6" upper_limit="86.8"/>
                    <measurement group_id="O4" value="82.0" lower_limit="75.2" upper_limit="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Other Lipids and Apolipoproteins</title>
        <description>Change from baseline (LOCF, ITT population)</description>
        <time_frame>28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O2">
            <title>DRL-17822 50 mg</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O3">
            <title>DRL-17822 150 mg</title>
            <description>Once daily after breakfast</description>
          </group>
          <group group_id="O4">
            <title>DRL-17822 300 mg</title>
            <description>Once daily after breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Other Lipids and Apolipoproteins</title>
          <description>Change from baseline (LOCF, ITT population)</description>
          <population>ITT with LOCF</population>
          <units>percentage change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="-5.8" upper_limit="15.5"/>
                    <measurement group_id="O2" value="-15.4" lower_limit="-26.3" upper_limit="-4.5"/>
                    <measurement group_id="O3" value="-18.7" lower_limit="-29.5" upper_limit="-7.9"/>
                    <measurement group_id="O4" value="-39.4" lower_limit="-50.1" upper_limit="-28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C/LDL-C Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="-41.2" upper_limit="42.3"/>
                    <measurement group_id="O2" value="140.6" lower_limit="97.9" upper_limit="183.3"/>
                    <measurement group_id="O3" value="240.0" lower_limit="197.8" upper_limit="282.2"/>
                    <measurement group_id="O4" value="385.2" lower_limit="343.5" upper_limit="427.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="-2.9" upper_limit="5.8"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-5.3" upper_limit="3.5"/>
                    <measurement group_id="O3" value="-0.8" lower_limit="-5.2" upper_limit="3.5"/>
                    <measurement group_id="O4" value="-0.8" lower_limit="-5.1" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="-7.7" upper_limit="16.7"/>
                    <measurement group_id="O2" value="-14.2" lower_limit="-26.7" upper_limit="-1.7"/>
                    <measurement group_id="O3" value="0.9" lower_limit="-11.5" upper_limit="13.2"/>
                    <measurement group_id="O4" value="-11.3" lower_limit="-23.5" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apo A1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="-4.1" upper_limit="7.7"/>
                    <measurement group_id="O2" value="35.0" lower_limit="29.0" upper_limit="41.1"/>
                    <measurement group_id="O3" value="44.8" lower_limit="38.8" upper_limit="50.8"/>
                    <measurement group_id="O4" value="59.1" lower_limit="53.2" upper_limit="65.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apo B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="-2.4" upper_limit="8.2"/>
                    <measurement group_id="O2" value="-15.1" lower_limit="-20.5" upper_limit="-9.7"/>
                    <measurement group_id="O3" value="-22.2" lower_limit="-27.6" upper_limit="-16.9"/>
                    <measurement group_id="O4" value="-28.9" lower_limit="-34.2" upper_limit="-23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apo E</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="-13.7" upper_limit="21.4"/>
                    <measurement group_id="O2" value="2.6" lower_limit="-15.3" upper_limit="20.6"/>
                    <measurement group_id="O3" value="10.9" lower_limit="-6.9" upper_limit="28.6"/>
                    <measurement group_id="O4" value="32.5" lower_limit="15.0" upper_limit="50.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apo Lp(a)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="-34.4" upper_limit="40.0"/>
                    <measurement group_id="O2" value="-26.2" lower_limit="-63.9" upper_limit="11.4"/>
                    <measurement group_id="O3" value="10.0" lower_limit="-26.2" upper_limit="46.2"/>
                    <measurement group_id="O4" value="-37.7" lower_limit="-75.4" upper_limit="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From randomization to 28 days of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Capsule</title>
          <description>Once daily after breakfast</description>
        </group>
        <group group_id="E2">
          <title>DRL-17822 50 mg</title>
          <description>Once daily after breakfast</description>
        </group>
        <group group_id="E3">
          <title>DRL-17822 150 mg</title>
          <description>Once daily after breakfast</description>
        </group>
        <group group_id="E4">
          <title>DRL-17822 300 mg</title>
          <description>Once daily after breakfast</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <description>Pericecal abscess treated with antibiotic therapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Treated as an outpatient</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kent Allenby, MD</name_or_title>
      <organization>Proprietary Products, Dr. Reddy's Laboratories, Inc.</organization>
      <phone>609-375-9855</phone>
      <email>kallenby@drreddys.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

